Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TVGNW SEC filings page.
This page shows Tevogen Inc. Warrant (TVGNW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending is expanding ahead of operating scale, while negative equity and financing needs define how Tevogen currently operates.
FY2025’s net loss of$26.3M was materially larger than operating cash outflow of$12.3M , so accounting losses did not translate one-for-one into cash use; non-cash charges or working-capital movements softened the cash impact. Because free cash flow was-$12.4M against operating cash flow of-$12.3M , capital spending was comparatively minor and the cash requirement was chiefly operating rather than reinvestment-driven.
The cost structure expanded sharply from FY2023 to FY2025: SG&A rose
The balance sheet is structurally tight: FY2025 liabilities were
Financial Health Signals
We do not publish a peer-relative financial health score for Tevogen Inc. Warrant, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Tevogen Inc. Warrant passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Tevogen Inc. Warrant reported a net loss of $26.3M while operations used $12.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Tevogen Inc. Warrant's EBITDA was -$6.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Tevogen Inc. Warrant reported a net loss of $7.0M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Tevogen Inc. Warrant held $145K in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
None of these metrics is reported for Q3 2026.
Capital Allocation
Tevogen Inc. Warrant invested $3.0M in research and development in Q3 2026. This represents a decrease of 4.8% from the same quarter a year earlier. Against the prior quarter it is down 9.7%.
Not reported for Q3 2026.
Not reported for Q3 2026.
TVGNW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.0M-4.8% | $3.3M+21.6% | $3.1M-1.9% | $2.1M-25.8% | $3.1M-4.6% | $2.7M-34.5% | $3.2M-84.6% | $2.8M+212.4% |
| SG&A Expenses | $3.9M+50.4% | $2.4M-13.3% | $2.3M-68.4% | $2.5M-61.6% | $2.6M-7.3% | $2.7M-38.7% | $7.2M-17.7% | $6.5M+492.7% |
| Operating Income | -$6.9Mn/m | -$5.7Mn/m | -$5.4Mn/m | -$4.6M | -$5.7Mn/m | -$5.4Mn/m | -$10.4Mn/m | N/A |
| EBITDA | -$6.9Mn/m | -$5.6Mn/m | -$5.3Mn/m | -$4.5M | -$5.7Mn/m | -$5.2Mn/m | -$10.3Mn/m | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $25K-84.2% | N/A |
| Net Income | -$7.0Mn/m | -$5.8Mn/m | -$5.4Mn/m | -$4.7Mn/m | -$5.7Mn/m | -$5.5Mn/m | -$10.4M-192.0% | -$9.4Mn/m |
| EPS (Basic) | -$1.76 | -$1.52 | -$1.61 | N/A | -$1.50 | -$1.71 | -$3.25 | -$0.06 |
| EPS (Diluted) | -$1.76 | -$1.52 | -$1.61 | N/A | -$1.50 | -$1.71 | -$3.25 | -$0.06 |
| Diluted Shares (Avg) | 4M | 4M | 3M | N/A | 4M | 3M | 3M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
TVGNW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.5M-21.8% | $4.7M+10.7% | $4.9M+20.8% | $4.4M+26.6% | $4.5M+4.8% | $4.3M+29.0% | $4.1M+21.1% | $3.5M-37.1% |
| Current Assets | $841K-60.4% | $2.0M-2.5% | $2.1M-30.4% | $1.5M-34.8% | $2.1M-39.9% | $2.1M-15.8% | $3.1M+28.2% | $2.4M+37.0% |
| Cash & Equivalents | $145K-86.0% | $1.1M+57.9% | $692K-64.9% | $0n/m | $1.0M-55.5% | $685K-39.6% | $2.0M+49.9% | $0n/m |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $14.8M+20.2% | $13.6M-1.0% | $14.8M+25.2% | $12.6M+24.5% | $12.3M+17.5% | $13.8M+25.7% | $11.8M+28.7% | $10.1M-89.9% |
| Current Liabilities | $6.4M-5.4% | $6.2M-23.9% | $7.3M-16.6% | $7.1M-21.8% | $6.7M-35.3% | $8.1M-23.8% | $8.7M-2.4% | $9.0M-89.4% |
| Non-Current Liabilities | $8.4M+51.2% | $7.5M+31.6% | $7.5M+143.9% | $5.5M+407.7% | $5.6M+8591.6% | $5.7M+1607.3% | $3.1M+1249.4% | $1.1M-92.4% |
| Total Equity | -$11.3Mn/m | -$8.9Mn/m | -$9.8Mn/m | -$8.2Mn/m | -$7.8Mn/m | -$9.5Mn/m | -$7.7Mn/m | -$6.7Mn/m |
| Retained Earnings | -$158.7Mn/m | -$150.9Mn/m | -$145.1Mn/m | -$139.7Mn/m | -$135.0Mn/m | -$129.3Mn/m | -$123.8Mn/m | -$113.4Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TVGNW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0Mn/m | -$3.0Mn/m | -$2.7Mn/m | -$2.2Mn/m | -$3.6Mn/m | -$3.2Mn/m | -$3.3Mn/m | -$3.0Mn/m |
| Depreciation & Amortization | $45K+66.2% | $60K-79.3% | $59K-44.0% | $86K-17.2% | $27K-73.2% | $291K+190.8% | $105K+7.2% | $104K+2.7% |
| Stock-Based Compensation | N/A | N/A | $2.8M-60.9% | N/A | $3.2M-2.5% | $3.2M-21.8% | $7.3M-72.3% | N/A |
| Financing Cash Flow | $1.0M-74.6% | $3.4M+78.7% | $2.9M-28.2% | $1.8M-12.0% | $4.0M-20.0% | $1.9M-32.1% | $4.0M+64.7% | $2.0M+373.7% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TVGNW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$8.2M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Tevogen Inc. Warrant TVGNW | FY2025 | N/A | -$26.3M | N/A | N/A | — |
| Kyverna Therapeutics, Inc. KYTX | FY2025 | N/A | -$161.3M | N/A | $269.3M | — |
| Sanofi SNY | FY2025 | $54.8B | $9.2B | 16.7% | $111.7B | 61/100 |
| Schrodinger, Inc. SDGR | FY2025 | $255.9M | -$103.3M | -40.4% | $1.7B | 74/100 |
| Zymeworks Inc. ZYME | FY2025 | $106.0M | -$81.1M | -76.6% | $1.8B | 79/100 |
| Absci Corporation ABSI | FY2025 | $2.8M | -$115.2M | N/A | $1.3B | 53/100 |
Where Tevogen Inc. Warrant Ranks
Frequently Asked Questions
No, Tevogen Inc. Warrant (TVGNW) reported a net loss of $26.3M in fiscal year 2025.
Tevogen Inc. Warrant (TVGNW) had EBITDA of -$25.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Tevogen Inc. Warrant (TVGNW) recorded an outflow of $12.4M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Tevogen Inc. Warrant (TVGNW) recorded an outflow of $12.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Tevogen Inc. Warrant (TVGNW) had $4.4M in total assets as of fiscal year 2025, including both current and long-term assets.
Tevogen Inc. Warrant (TVGNW) invested $64K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Tevogen Inc. Warrant (TVGNW) invested $11.1M in research and development during fiscal year 2025.
Tevogen Inc. Warrant (TVGNW) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Tevogen Inc. Warrant (TVGNW) had a return on assets of -599.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, Tevogen Inc. Warrant (TVGNW) held $0 in cash, cash equivalents and investments, and reported an operating cash outflow of $12.3M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Tevogen Inc. Warrant (TVGNW) has negative shareholder equity of -$8.2M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Tevogen Inc. Warrant (TVGNW) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Tevogen Inc. Warrant (TVGNW) reported a net loss of $26.3M while operations used $12.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.